SCHEMBL2221066

SCHEMBL2221066

[CH2]OC(=O)CCCCCCCCCCC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.61
LMNA P02545 2/20 0.57
TSHR P16473 5/20 0.57
PAM P19021 2/20 0.55
CES2 O00748 3/20 0.54
CES1 P23141 3/20 0.54
MAPT P10636 1/20 0.53
MAPK1 P28482 1/20 0.53
PPARG P37231 6/20 0.52
PPARD Q03181 6/20 0.52
PPARA Q07869 6/20 0.52
GPR84 Q9NQS5 5/20 0.52
HDAC11 Q96DB2 5/20 0.52
ALDH1A1 P00352 2/20 0.52
TLR2 O60603 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
FABP4 P15090 2/20 0.52
PTPN1 P18031 2/20 0.52
SLC22A6 Q4U2R8 1/20 0.52
SLC22A8 Q8TCC7 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2257511 1.00 DGKA (0.61) DGKALMNATSHRPAMCES2
SCHEMBL2259990 1.00 DGKA (0.61) DGKALMNATSHRPAMCES2
SCHEMBL2218438 1.00 DGKA (0.61) DGKALMNATSHRPAMCES2
SCHEMBL2258838 1.00 DGKA (0.61) DGKALMNATSHRPAMCES2
SCHEMBL2254789 1.00 DGKA (0.61) DGKALMNATSHRPAMCES2
SCHEMBL2256002 1.00 DGKA (0.61) DGKALMNATSHRPAMCES2
SCHEMBL2255838 1.00 DGKA (0.61) DGKALMNATSHRPAMCES2
SCHEMBL2255273 1.00 DGKA (0.61) DGKALMNATSHRPAMCES2
SCHEMBL2255255 1.00 DGKA (0.61) DGKALMNATSHRPAMCES2
SCHEMBL2255062 1.00 DGKA (0.61) DGKALMNATSHRPAMCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4873322-A VIRICIDES, HERPES AND INFLUENZA; LINKED TO CEPHALIN COMPONENTS CIBA-GEIGY CORPORATION (US) 1989-10-10 US claimed
EP-0074653-B1 NEW CEPHEM COMPOUNDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-04-26 EP claimed
EP-0233837-A2 Saccharide derivatives and method for their preparation CIBA-GEIGY AG (CH) 1987-08-26 EP claimed
US-4521413-A Cephem compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1985-06-04 US claimed
EP-0074653-A2 New cephem compounds, processes for their preparation, pharmaceutical compositions containing them and intermediate products for their preparation FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-03-23 EP claimed
CN-118043437-A Lubricating oil composition, lubricating method and transmission 出光兴产株式会社 2024-05-14 CN disclosed
EP-3279292-B1 LUBRICANT OIL COMPOSITION AND INTERNAL-COMBUSTION-ENGINE FRICTION REDUCTION METHOD IDEMITSU KOSAN CO (JP) 2024-05-01 EP disclosed
EP-4321164-A2 COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY ViiV Healthcare UK (No.5) Limited (GB) 2024-02-14 EP disclosed
US-11883394-B2 Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia ALKERMES PHARMA IRELAND LIMITED (IE) 2024-01-30 US disclosed
CN-114846125-B Lubricating oil composition 出光兴产株式会社 2024-01-16 CN disclosed
EP-3784349-B1 COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY VIIV HEALTHCARE UK NO 5 LTD (GB) 2023-12-27 EP disclosed
CN-112494492-B Aripiprazole prodrug compositions 阿尔科姆斯制药爱尔兰有限公司 2023-08-25 CN disclosed
EP-0335390-A2 Novel cephalosporin compounds SAGAMI CHEMICAL RESEARCH CENTER (JP) 1989-10-04 EP disclosed
US-4808620-A ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETIC, ANTIALLERGENS, ANTIARTHRITIC, ANTIRHEUMATIC AGENTS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1989-02-28 US disclosed
EP-0254241-A1 Pyrazolopyridine compounds, their preparation and use Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1988-01-27 EP disclosed
EP-0233837-A2 Saccharide derivatives and method for their preparation CIBA-GEIGY AG (CH) 1987-08-26 EP disclosed
EP-0046270-B1 NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM INTERx RESEARCH CORPORATION (US) 1986-05-21 EP disclosed
US-4443435-A ANTICARCINOGENS, HYPOTENSIVE AGENTS, HYPERTHYROIDISM MERCK & CO., INC. (US) 1984-04-17 US disclosed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP disclosed
EP-0038541-A1 Novel prodrugs of biologically active agents containing mercapto groups, process for preparing and therapeutically effective composition containing the same MERCK & CO. INC. (US) 1981-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11883394-B2 Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia SAMM50, SLC6A4, RAP2C DGKA 2825/4885LMNA 4573/4885TSHR 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.